Compare
Kiniksa Pharmaceuticals International, plc vs Ultragenyx Pharmaceutical Inc. vs Axsome Therapeutics, Inc. vs Amphastar Pharmaceuticals, Inc.
| Latest fiscal year | Kiniksa Pharmaceuticals International, plc KNSA | Ultragenyx Pharmaceutical Inc. RARE | Axsome Therapeutics, Inc. AXSM | Amphastar Pharmaceuticals, Inc. AMPH |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $677.56M | $673.00M | $638.50M | $719.89M |
| Revenue growth (YoY) | +60.1% | +20.2% | +65.5% | -1.7% |
| Gross margin | 88.5% (computed) | n/a | n/a | 49.5% |
| Operating margin | 11.4% | -79.5% | -26.1% | 19.5% |
| Net margin | 8.7% | -85.4% | -28.7% | 13.6% |
| Net income | $59.01M | -$575.00M | -$183.17M | $98.09M |
| EPS (Diluted) | $0.75 | -$5.83 | -$3.68 | $2.03 |
| Operating cash flow | $137.99M | -$466.00M | -$93.41M | $156.12M |
| Free cash flow | $136.42M | -$472.00M | -$93.89M | $121.23M |
| Cash & equivalents | $165.60M | $421.00M | $322.93M | $170.18M |
| Total assets | $763.63M | $1.53B | $689.80M | $1.63B |
| Total liabilities | $196.03M | $1.60B | $601.51M | $840.49M |
| Shareholders' equity | $567.61M | -$80.00M | $88.30M | $788.80M |
| Return on year-end equity | 10.4% | n/a | -207.5% | 12.4% |
| Shares outstanding | n/a | 96.60M | 50.88M | 45.65M |
Revenue, most recent five fiscal years
| Fiscal year | Kiniksa Pharmaceuticals International, plc | Ultragenyx Pharmaceutical Inc. | Axsome Therapeutics, Inc. | Amphastar Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $677.56M Ended 2025-12-31 | $673.00M Ended 2025-12-31 | $638.50M Ended 2025-12-31 | $719.89M Ended 2025-12-31 |
| 1 year earlier | $423.24M Ended 2024-12-31 | $560.00M Ended 2024-12-31 | $385.69M Ended 2024-12-31 | $731.97M Ended 2024-12-31 |
| 2 years earlier | $270.26M Ended 2023-12-31 | $434.00M Ended 2023-12-31 | $270.60M Ended 2023-12-31 | $644.39M Ended 2023-12-31 |
| 3 years earlier | $220.18M Ended 2022-12-31 | $363.33M Ended 2022-12-31 | $50.04M Ended 2022-12-31 | $498.99M Ended 2022-12-31 |
| 4 years earlier | $38.54M Ended 2021-12-31 | $351.41M Ended 2021-12-31 | n/a | $437.77M Ended 2021-12-31 |